Stock Quote (NASDAQ: VTUS)
Price:
1.16
Change:
+ 0.03
Day High:
1.19
Day Low:
1.12
Volume:
458,900
4:00 PM ET on Apr 22, 2014
Delayed at least 20min., by eSignal.
Press Releases

SHAREHOLDER TOOLS
Briefcase Printed Materials Email Alerts
Download Center snapshot RSS Mobile Investor

PROXY STATEMENT
2011 Annual Report
2012 Proxy Statement
All Releases
View Summary Ventrus Biosciences Receives Date for Type B Pre-NDA Meeting With FDA for DOLIZEM (Diltiazem Hydrochloride Cream) in Anal Fissures
Apr 4, 2014
PDF 10.8 KB Add to Briefcase
View Summary Ventrus Biosciences Announces Results From Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure
Feb 12, 2014
PDF 13.3 KB Add to Briefcase
View Summary Ventrus Biosciences Completes Enrollment of Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure
Nov 25, 2013
PDF 56.4 KB Add to Briefcase
View Summary Ventrus Biosciences Announces Positive Results From Clinical Dermal Safety and Pharmacokinetic Studies of Diltiazem (VEN 307)
Sep 11, 2013
PDF 15.4 KB Add to Briefcase
View Summary Ventrus Biosciences Announces Poster Presentation on the Quality of Compounded Topical Diltiazem Hydrochloride Formulations for Anal Fissure at the American Pharmacists Association Meeting
Mar 1, 2013
PDF 12.4 KB Add to Briefcase
View Summary Ventrus Biosciences to Present at the Leerink Swann Global Healthcare Conference
Feb 11, 2013
PDF 10.3 KB Add to Briefcase
View Summary Ventrus Biosciences Announces Full Exercise of Overallotment Option by Underwriters
Feb 7, 2013
PDF 11.7 KB Add to Briefcase
View Summary Ventrus Biosciences Announces $20 Million Financing
Jan 30, 2013
PDF 12.2 KB Add to Briefcase
View Summary Ventrus Biosciences Announces Proposed Public Offerings of Common Stock and Series A Convertible Preferred Stock
Jan 29, 2013
PDF 11.8 KB Add to Briefcase
View Summary Ventrus Biosciences Reports Third Quarter 2012 Financial Results
Nov 13, 2012
PDF 11.7 KB Add to Briefcase
View Summary Ventrus Biosciences to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Nov 8, 2012
PDF 9.5 KB Add to Briefcase
View Summary Ventrus Biosciences Receives FDA Written Feedback, Targets NDA Filing for Diltiazem (VEN 307) in Anal Fissures Following Second Phase 3 Study
Nov 5, 2012
PDF 14.9 KB Add to Briefcase
View Summary Ventrus Biosciences Appoints JP Benya Vice President, Commercial Operations and Business Development
Sep 24, 2012
PDF 12.7 KB Add to Briefcase
View Summary Ventrus Biosciences to Present at Upcoming Investor Conferences in September
Aug 29, 2012
PDF 9.0 KB Add to Briefcase
View Summary Ventrus Biosciences Reports Second Quarter 2012 Financial Results
Aug 9, 2012
PDF 12.0 KB Add to Briefcase
View Summary Ventrus Biosciences Announces Results From Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease
Jun 25, 2012
PDF 14.4 KB Add to Briefcase
View Summary Ventrus to Present at the Jefferies 2012 Global Healthcare Conference
May 30, 2012
PDF 8.6 KB Add to Briefcase
View Summary Ventrus to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 15, 2012
PDF 9.2 KB Add to Briefcase
View Summary Ventrus Biosciences Announces Positive Results From Pivotal Phase 3 Trial of Diltiazem (VEN 307) in Patients With Anal Fissures
May 14, 2012
PDF 69.8 KB Add to Briefcase
View Summary Ventrus Biosciences Reports First Quarter 2012 Financial Results
May 9, 2012
PDF 14.1 KB Add to Briefcase
Showing 1-20 of 45 Page: 1 2 3  Next 20
Add to Briefcase = add release to Briefcase
 
Home About Ventrus Product Pipeline Contact Investor Relations